Any price around that offering price is a safe buy, and as we seen yesterday with the slightest news this thing has the ability to run in a heart beat!

also a reverse split name that closed offering, this is the hot theme right now, $PALI $HOTH Bio is hot this month.

$PALI Yummy dips offering closed so no risk of dilution in the near time

$PALI offering closed moving up

$PALI AH run up following offering closing!

$PALI closing offering AH, easy +30%

$PALI great opportunity imo offering closes AH too

That's a great thing so u fud spreaders calling it a offering are full of crap,stop your bs

$PALI excited for next week looking forward to the offering closing and any new news.

$12 offering.. easy $4+

$bxrx and $grom had offerings and are up nicely today.

$TGTX FDA approval for Billion dollar MS drug — great things in store 2023 $DRMA just officially dropped offering, makes me feel company has something good up it’s sleeve.

Probably get a bonus this year for all the fine work she's done with reverse splits and offerings.

Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.

$TGTX makes a lot of sense to do a 300M offering here imo

What stuck out was the combined value proposition: efficacy, safety, convenience, marketability, pricing, etc.

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

$TGTX FDA approval for Billion dollar MS drug — great things in store 2023 $DRMA just officially dropped offering, makes me feel company has something good up it’s sleeve.

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

Amazing positive news from the TGTX 20221229 conference call, FDA approved, 🚨🔥🚨 Ublituximab Briumvi: 1) No need for additional funds, no offering, no need for capital raise, because 220 million in cash reserves expected to last until mid 2024.